Sequential pseudoallogeneic CAR20/22/19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report
Our findings suggest that pseudoallogeneic CAR-T therapy was safe and effective in patients with DLBCL who experienced relapse after allo-HSCT. Sequential administration of CAR20/22/19 T cells may have reduced the antigen escape relapse in DLBCL. For patients with DLBCL relapse after allo-HSCT, larger trials are required to validate the safety and effectiveness of pseudoallogeneic CAR-T therapy as well as its ability to lower the rate of antigen escape relapse.
Authors
- Shaomei Feng
- Defeng Zhao
- Zhihui Li (ORCID: https://orcid.org/0000-0001-5356-932X)
- Weicheng Liu (ORCID: https://orcid.org/0000-0001-6360-3544)
- Biping Deng (ORCID: https://orcid.org/0000-0002-3244-9174)
- Yu Xiong
- Qinlong Zheng (ORCID: https://orcid.org/0000-0002-8433-3691)
Institutions
- Beijing United Family Hospital (CN)
- Wuhan University (CN)
- Health Commission of Anhui Province (CN)
- Wuhan Prevention and Treatment Center for Occupational Diseases (CN)
- 302 Military Hospital of China (CN)
- Zhongnan Hospital of Wuhan University (CN)
- China National Building Materials Group (China) (CN)
- Beijing Fengtai Hospital (CN)
- Wuhan Center for Disease Control and Prevention (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1687478
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00